Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Oxford BioMedica ( (GB:OXB) ) has shared an update.
Oxford Biomedica has announced that its lentiviral vector manufacturing technology will support Boehringer Ingelheim’s new Phase I/II LENTICLAIR™ 1 trial. This trial, evaluating an innovative gene therapy for cystic fibrosis, highlights OXB’s role in the ongoing collaboration with Boehringer Ingelheim, reflecting its reputation as a trusted partner in advancing pioneering gene therapies addressing unmet medical needs.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company provides viral vector development and manufacturing expertise for lentivirus, adeno-associated virus, adenovirus, and other viral vector types. OXB’s capabilities range from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise. Headquartered in Oxford, UK, the company operates facilities in the UK, France, and the US.
YTD Price Performance: -0.57%
Average Trading Volume: 7,043
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $516.1M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.
